The effect of probiotics consumption on liver functio

Phase 3

Recruiting

• Conditions: K83.0; Cholangitis; Primary Sclerosing Cholangitis.

• Registration Number: IRCT20200628047940N3
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 August 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

Patients with a definitive diagnosis of primary sclerosing cholangitis(PSC)
Patients' informed consent to participate in the study

Exclusion Criteria

Neurological disease
Chronic alcoholic fatty liver
Chronic hepatitis B, C
Wilson disease
Hemochromatosis disease
Secondary sclerosing cholangitis
Primary cirrhosis of the bile ducts
Benign or malignant tumor of the liver or bile ducts
Peritonitis
Ascites
Variceal bleeding
Inflammation of the brain caused by hepatitis in the past 2 months
Consumption of probiotics, prebiotics, synbiotics or antibiotics 4 weeks before the start of the study
High protein diet
Active microbial infection
Autoimmune disease or the use of immunosuppressive drugs
Probability of liver transplantation in the next year based on secondary sclerosing cholangitis risk score Mayo
Alpha antitrypsin deficiency
Consumption of ursodeoxycholic acid
Consumption of alcohol or drugs
Pregnancy and lactation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Alkaline phosphatase changes. Timepoint: Before the start of study and one month after the end of taking probiotics and placebo. Method of measurement: Alkaline phosphatase test.